VARC-3 defined outcome of valve-in-valve transcatheter aortic valve implantation in stentless compared with stented aortic bioprostheses.
Jean-Honoré SteulMohamed Abdel-WahabTomasz StankowskiStephan HaussigFelix J WoitekTomasz GasiorLisa CrusiusLuise KnorrFelicitas V MüllerDirk FritzschePhilipp KieferUtz KappertDavid HolzheyAxel LinkeNorman MangnerPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2023)
SL and ST ViV-TAVI led to comparable short-term outcomes according to VARC-3- defined endpoints and similar mortality rates up to 5 years of follow-up. VARC-3 defined technical success, device success, and early safety as well as 5-year all-cause mortality in patients undergoing valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) into stentless (SL) compared with stented (ST) failed aortic bioprostheses.
Keyphrases
- aortic valve
- transcatheter aortic valve implantation
- aortic valve replacement
- aortic stenosis
- transcatheter aortic valve replacement
- patients undergoing
- left ventricular
- ejection fraction
- cardiovascular events
- risk factors
- heart failure
- coronary artery disease
- pulmonary hypertension
- pulmonary arterial hypertension